INmune Bio Cash Flow Statement 2017-2025 | INMB

Net Income/Loss

$-42.082

$-30.008

$-27.299

$-30.34

$-12.099

$-7.678

$-12.44

$-0.832

Total Depreciation And Amortization - Cash Flow

$0.079

$0.224

$0.239

$0.126

Other Non-Cash Items

$7.605

$7.368

$7.238

$4.796

$3.112

$2.555

$10.001

$0.05

Total Non-Cash Items

$7.684

$7.592

$7.477

$4.922

$3.112

$2.555

$10.001

$0.05

Change In Accounts Receivable

Change In Inventories

Change In Accounts Payable

Change In Assets/Liabilities

$2.409

$8.265

$-4.617

$-5.546

$-1.032

$-0.129

$-0.134

$-0.219

Total Change In Assets/Liabilities

$1.037

$10.436

$-2.864

$-3.086

$0.044

$-0.261

$0.38

$0.02

Cash Flow From Operating Activities

$-33.361

$-11.98

$-22.686

$-28.504

$-8.943

$-5.385

$-2.059

$-0.762

Net Change In Property, Plant, And Equipment

Net Change In Intangible Assets

$-15

$-0.1

Net Acquisitions/Divestitures

Net Change In Short-term Investments

Net Change In Long-Term Investments

Net Change In Investments - Total

Investing Activities - Other

Cash Flow From Investing Activities

$-15

$-0.1

Net Long-Term Debt

$-10

$-5

$14.951

Net Current Debt

Debt Issuance/Retirement Net - Total

$-10

$-5

$14.951

Net Common Equity Issued/Repurchased

$28.211

$0.775

$0.729

$81.406

$23.895

$12.209

$0.9

$2.056

Net Total Equity Issued/Repurchased

$28.211

$0.775

$0.729

$81.406

$23.895

$12.209

$0.9

$2.056

Total Common And Preferred Stock Dividends Paid

Financial Activities - Other

Cash Flow From Financial Activities

$18.211

$-4.225

$0.729

$96.357

$23.895

$12.209

$0.9

$2.056

Net Cash Flow

$-14.926

$-16.305

$-22.657

$52.843

$14.971

$6.809

$-1.185

$1.229

Stock-Based Compensation

$7.605

$7.368

$7.149

$4.796

$3.112

$4.097

$10.001

$0.2

Common Stock Dividends Paid